LPOXY Therapeutics, Inc. Acquires Key Assets from Xeno Biosciences Inc. to Advance C. difficile Prevention Therapy
Acquiring Company
LPOXY Therapeutics
Acquired Company
Xeno Biosciences
Platte CityCambridgeHealth CareBiotechnologyDescription
LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on infectious disease prevention, has signed a term sheet to acquire key strategic assets from Xeno Biosciences Inc. These assets include regulatory filings, documentation, and comprehensive CMC data, which will support the advancement of SIDIPREV™, a novel therapy aimed at preventing Clostridioides difficile infections in hospitalized patients receiving antibiotic treatment. Additionally, Xeno Biosciences Inc. will become a shareholder in LPOXY Therapeutics and may receive milestone payments totaling up to $7.5 million.
Quick answer
LPOXY Therapeutics is acquiring Xeno Biosciences, announced January 3, 2025. LPOXY Therapeutics is based in Platte City, Missouri, United States.
- How much did LPOXY Therapeutics pay for Xeno Biosciences?
- The deal value was not disclosed.
- What does LPOXY Therapeutics do?
- LPOXY Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention.
- Where are LPOXY Therapeutics and Xeno Biosciences based?
- LPOXY Therapeutics is based in Platte City, Missouri, United States. Xeno Biosciences is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at LPOXY Therapeutics?
- Fundz holds 1 contact at LPOXY Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Health Care and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Novartis to acquire Anthos Therapeutics for up to $3.1 Billion, $3.1B (February 11, 2025)
- Pan-Am Dental completes strategic acquisitions of JB Dental Lab and Avaneer Dental Studio, solidifying its position as a top 10 dental lab group (February 10, 2025)
- BioNTech completes acquisition of Biotheus to strengthen oncology strategy (February 4, 2025)
- Exicure, Inc. completes acquisition of GPCR Therapeutics USA Inc. to enhance its pipeline for cell and gene therapies (January 22, 2025)
- Cycle Pharmaceuticals completes acquisition of Banner Life Sciences, LLC to expand MS product portfolio (January 13, 2025)
- Vivo Infusion completes acquisition of Neurology Institute of San Antonio and Vista Infusions to expand infusion services (January 9, 2025)
Who to call at LPOXY Therapeutics, and when
When LPOXY Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day LPOXY Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at LPOXY Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at LPOXY Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment LPOXY Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Xeno Biosciences?
Xeno Biosciences was acquired by LPOXY Therapeutics, based in Platte City. The deal was reported on January 3, 2025. LPOXY Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention. LPOXY Therapeutics is privately held and operates in Health Care.
When did LPOXY Therapeutics acquire Xeno Biosciences?
LPOXY Therapeutics's acquisition of Xeno Biosciences was reported on January 3, 2025. LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on infectious disease prevention, has signed a term sheet to acquire key strategic assets from Xeno Biosciences Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Xeno Biosciences do?
Xeno Biosciences is a biotechnology company pioneering a novel class of treatments for metabolic diseases. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.